Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Contieri Roberto, Claps Francesco, Hurle Rodolfo, Buffi Nicolò Maria, Lughezzani Giovanni, Lazzeri Massimo, Aveta Achille, Pandolfo Savio, Porpiglia Francesco, Fiori Cristian, Barone Biagio, Crocetto Felice, Ditonno Pasquale, Lucarelli Giuseppe, Lasorsa Francesco, Busetto Gian Maria, Falagario Ugo, Giudice Francesco Del, Maggi Martina, Cantiello Francesco, Borghesi Marco, Terrone Carlo, Bove Pierluigi, Antonelli Alessandro, Veccia Alessandro, Mari Andrea, Luzzago Stefano, Todea-Moga Ciprian, Minervini Andrea, Musi Gennaro, Fallara Giuseppe, Mistretta Francesco Alessandro, Bianchi Roberto, Tozzi Marco, Soria Francesco, Gontero Paolo, Marchioni Michele, Janello Letizia M I, Terracciano Daniela, Russo Giorgio I, Schips Luigi, Perdonà Sisto, Tataru Octavian S, Vartolomei Mihai D, Autorino Riccardo, Catellani Michele, Sighinolfi Chiara, Montanari Emanuele, Stasi Savino M Di, Rocco Bernardo, de Cobelli Ottavio, Ferro Matteo
Аннотация
PATIENT AND METHODS: Outcomes from 1313 patients with nonmuscle invasive bladder cancer treated with TURBT, re-TURBT and BCG instillations at 13 academic hospital centers, since 2002, has been included in this retrospective study. The study variables, including cumulative smoking exposure have been analyzed. A multivariable Cox proportional hazard model was used to assess associations between smoking variables and disease progression and repeated in the EAU high risk and very high-risk group. The statistical significance threshold was set at 0.05, and the statistical analysis was performed using Stata/SE version 17 (StataCorp, College Station, TX, USA).
RESULTS: Cox regression analysis revealed in 1313 patients diagnosed with T1G3 NMIBC that patients with a history of heavy and long-term smoking faced a more than twofold increased risk of disease progression compared to nonsmoker patients (HR 2.35; 95% CI: 1.7-3.2; P < 0.01) and a significantly poorer PFS for patients with a history of heavy long-term smoke exposure (P < 0.01). Patients with heavy long-term smoking exposure according to the EAU21 high-risk group had a PFS comparable to very high-risk patients and high-risk patients with heavy long-term smoking exposure showed a higher risk of progression when compared to the high-risk group (HR 1.4; 95% CI: 1.3-1.6; P < 0.01).
CONCLUSIONS: This study adds valuable information on the relationship between smoking and the progression of NMIBC and BCG therapy. The findings emphasize the need for healthcare providers to consider a patient's smoking history when managing NMIBC and express the need for individualized smoking cessation counseling and individualized treatment approach.